|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-19.00/--
|
企业价值
1.39M
|
资产负债 |
每股账面净值
21.32
|
现金流量 |
现金流量率
--
|
损益表 |
收益
24.09M
|
每股收益
14.61
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/01 02:17 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment. |